Neuro-Bio is a privately held biotech company focussed on development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimers, Parkinsons and Motor Neuron Diseases.
Neuro-Bio is validating the theory of its founding scientist, Susan Greenfield, which holds that, a peptide derived from the enzyme acetylcholinesterase (AChE) acts as a toxin and initiates a cycle of cell death and neurodegeneration in the adult brain.
Neuro-Bio is a privately held biotech company focussed on development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimers, Parkinsons and Motor Neuron Diseases.
Neuro-Bio is validating the theory of its founding scientist, Susan Greenfield, which holds that, a peptide derived from the enzyme acetylcholinesterase (AChE) acts as a toxin and initiates a cycle of cell death and neurodegeneration in the adult brain.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neuro-bio-limited” connections=”true” suffix=””]
The company has developed a method of intercepting and halting the action of the toxic AChE peptide on the receptor to arrest further cell death which is the major effect of many neurodegenerative disease.
In March 2017, Neuro-Bio Attracts Over $3 Million in Series A Investment to Develop a New Approach to Alzheimers Disease from US-based Kairos Ventures.
Recover your password.
A password will be e-mailed to you.